%A Wang Wenxian, Zhang Yiping %T Targeted therapy for small cell lung cancer %0 Journal Article %D 2015 %J Journal of International Oncology %R 10.3760/cma.j.issn.1673,422X.2015.06.014 %P 452-454 %V 42 %N 6 %U {https://gjzlx.sdfmu.edu.cn/CN/abstract/article_9670.shtml} %8 2015-06-08 %X argeted agents for small cell lung cancer (SCLC) include inhibitors of angiogenesis, tyrosine kinase inhibitors and signal transduction pathway inhibitors. Bevacizumab, a class of antiangiogenic agent, tends to have no effects on patients. The tyrosine kinase inhibitor, for example sunitinib, may be used as a monotherapy. Signaling inhibitors including Amuvatinib and LDE225 are undergoing phaseⅠand Ⅱ trials. Primary data show that SCLC is not sensitive to targeted therapy, needing more selection, so further studies are requested.